NCT02436928View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
H7N9 Influenza Vaccine
Interventions
BIOLOGICAL

AT-501 High Dose vaccine

Comparison of each dose of vaccine

BIOLOGICAL

AT-501 High Dose vaccine with Adjuvant

Comparison of each dose of vaccine

BIOLOGICAL

AT-501 Low Dose vaccine

Comparison of each dose of vaccine

BIOLOGICAL

AT-501 Low Dose vaccine with Adjuvant

Comparison of each dose of vaccine

Trial Locations (1)

Unknown

National Taiwan University Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Medigen Vaccine Biologics Corp.

INDUSTRY

NCT02436928 - A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter